Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Palo Alto Networks Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Palo Alto Networks Inc trades at $400.3 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 194× Nuvation Bio Inc. Class A Common Stock's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Palo Alto Networks Inc for 82 Days on average.
| NUVB | PANW | |
|---|---|---|
Market Cap | $1.71B | $331.76B |
Volume | 5,448,712 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $9.54 | $419.91 |
52-Week Low | $3.41 | $141.67 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $1.30B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Palo Alto Networks (PANW) trades at $398.50, down 5.1% today but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive analyst sentiment (72% buy ratings). Recent earnings beats and robust revenue growth to $9.22B in 2025 highlight fundamental strength, though valuation metrics appear elevated with P/E at 1,013.93 and P/S at 26.99. The company's AI-driven security platform and continuous defense services are driving market optimism.
Outlook remains positive given cybersecurity demand and AI integration, but premium valuation and rising costs pose risks. Revenue growth acceleration to $11.5B projected for 2026 supports bullish case, while net margin compression to 2.67% warrants monitoring. Analyst consensus target of $398.70 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
